Vista Pharmaceuticals Limited Share Price

Equities

VISTAPH6

INE427C01021

Pharmaceuticals

Market Closed - Bombay S.E. 11:00:51 29/05/2024 BST 5-day change 1st Jan Change
13.39 INR +3.72% Intraday chart for Vista Pharmaceuticals Limited +2.61% -8.73%

Financials

Sales 2022 3.94M 47.34K 3.71M Sales 2023 10.04M 120K 9.44M Capitalization 312M 3.74M 293M
Net income 2022 -8M -95.99K -7.52M Net income 2023 -56M -672K -52.66M EV / Sales 2022 118 x
Net Debt 2022 125M 1.5M 117M Net Debt 2023 97.55M 1.17M 91.73M EV / Sales 2023 40.8 x
P/E ratio 2022
-40.8 x
P/E ratio 2023
-5.44 x
Employees 30
Yield 2022 *
-
Yield 2023
-
Free-Float 26.74%
More Fundamentals * Assessed data
Dynamic Chart
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Vista Pharmaceuticals Limited Announces the Resignation of Mr. Nishant Talreja from the Post of Company Secretary, Compliance Officer and Key Managerial Personnel CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Vista Pharmaceuticals Limited Announces Change in Corporate Office Address CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Vista Pharmaceuticals Limited announced that it has received INR 61.895 million in funding CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Vista Pharmaceuticals Appoints Chairman MT
Vista Pharmaceuticals Limited Announces Executive Changes CI
Vista Pharmaceuticals Limited Approves Resignation of Narendra Gilaka as Independent Director of the Company CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 66.895 million in funding CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
More news
1 day+3.72%
1 week+2.61%
Current month-4.36%
1 month-4.36%
3 months-6.88%
6 months-18.75%
Current year-8.73%
More quotes
1 week
12.02
Extreme 12.02
13.56
1 month
12.02
Extreme 12.02
15.15
Current year
10.43
Extreme 10.43
17.55
1 year
8.09
Extreme 8.09
19.70
3 years
6.51
Extreme 6.51
19.70
5 years
4.51
Extreme 4.51
19.70
10 years
3.19
Extreme 3.192
56.15
More quotes
Managers TitleAgeSince
Chief Executive Officer - 13/10/22
Founder 73 24/01/91
Director of Finance/CFO - -
Members of the board TitleAgeSince
Founder 73 24/01/91
Director/Board Member 74 16/02/94
Director/Board Member 85 15/06/93
More insiders
Date Price Change Volume
29/05/24 13.39 +3.72% 2 199
28/05/24 12.91 +4.96% 2,845
27/05/24 12.3 -2.77% 3,381
24/05/24 12.65 +0.88% 10,349
23/05/24 12.54 -3.91% 13,289

Delayed Quote Bombay S.E., May 29, 2024 at 11:00 am

More quotes
Vista Pharmaceuticals Limited is an India-based company that is engaged in manufacturing and selling of pharmaceutical, medical, and veterinary preparations. The Company also sells the products to its related companies, which are engaged in the manufacture of formulations. It offers over the counter and prescription generic drug products, consisting of tablets, capsules and liquids covering various therapeutic categories. Its products include tablet dosage forms in the United States market, such as Sulfamethoxazole & Trimethoprim, Acetaminophen, Bismuth Subsalicylate, Bismuth Subgallate, Ferrous Gluconate, Ferrous Sulfate, Pyrantel Pamoate and Isoxsuprine HCl and tablet dosage forms in the non-United States market, such as Aspirin, Atenolol, Mebendazole, Nefidipine, Quinine Sulfate, Ranitidine HCl, Magnesium Trisilicate Compound, Aluminium Hydroxide, Folic Acid and Captopril. Its capsule dosage forms in the non-United States market include Indomethacin, Piroxicam and Nefidipine.
More about the company
  1. Stock Market
  2. Equities
  3. VISTAPH6 Stock